Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label randomized trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in previously untreated unresectable or metastatic melanoma
MOH_2022-10-18_012127Phase 3Recruiting
- Sponsor
- IO Biotech
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing IO102-IO103 + pembrolizumab with Pembrolizumab alone (2 arms). Primary endpoint: Progression-free survival. Started Oct 2022; status: recruiting.
02
Drugs
PD-L1/IDO peptide vaccinepembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2022-10-18_012127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-10-18_012127.